William Blair analyst Brian Weinstein says that even if shares of Exact Sciences move up significantly today, there will still be long-term value for investors. The USPSTF colorectal cancer site was updated yesterday to include a link to an article set for publication in a major medical journal within the next week, Weinstein tells investors in a research note. Clarification in the article places Exact Sciences' Cologuard on par with other screening strategies and makes it an "A" rated test for individuals age 50-75, the analyst notes. He writes, "We expect this will have material impact on reimbursement discussions as the Affordable Care Act requires all 'A' rated screening tests to be covered without co-pay." This should have a significant long-term impact on Cologuard uptake as lack of coverage is the primary barrier to adoption, Weinstein argues. He keeps an Outperform rating on shares of Exact Sciences.